- Kiran Mazumdar-Shaw transformed Biocon from a small garage-based startup into India’s largest biopharmaceutical company, focusing on affordable medicines and healthcare access.
- Through the Mazumdar-Shaw Medical Foundation and Biocon Foundation, she supports cancer care, medical research and healthcare infrastructure for underserved communitiesBiocon.
In 1978, Kiran Mazumdar-Shaw began a business called Biocon out of her Bangalore garage with 10,000 in capital, and a product no one in India was making. It was for industrial applications derived from enzyme-based bio fermentation. She was rejected for a loan when a bank manager asked whether it would help her run a brewery-type business, which seemed out of the question for a woman. Today, Biocon, the largest biopharmaceutical company in India, reported revenues of 16,470 crore for FY 25 and now makes life-saving medicines available in 120 countries.
Its CSR architecture, developed under the Mazumdar-Shaw Medical Foundation & Biocon Foundation, is built on the very framework that built the business. This kind of entrepreneurship in medicine and biology is currently making costly therapies available at prices that are affordable to all those who cannot now afford them.
Affordable medicines as both a business and a conscience
Mazumdar-Shaw believes as a core conviction that access and affordability are not charity but a fundamental healthcare right. This belief has shaped Biocon’s business model as directly as it has shaped its philanthropy. The company’s biosimilar programmes have produced affordable versions of trastuzumab (a cancer treatment), insulin and other biologics that would otherwise cost patients many times more. At Biocon, she built a dedicated CSR wing focused on healthcare, education and infrastructure. The Mazumdar-Shaw Medical Foundation supports translational research through programmes including the Mazumdar-Shaw Cancer Outreach initiative. This works to improve access to cancer diagnosis and treatment in communities that cannot afford the costs at tertiary hospitals.
Awards That Signal Something Real
In 2026, Mazumdar-Shaw was awarded the Lifetime Contribution to UK-India Relations award for her contributions to science, entrepreneurship, and cross-border healthcare partnerships. She also received the Honorary Fellowship of the Academy of Medical Sciences in the UK. These recognitions reflect a career as a credible manufacturer of high-quality, low-cost vaccines and biologics at a global scale, long before ‘vaccine nationalism’ or ‘generic drugs equity’ became talking points in international health policy. Forbes has featured her on its 2025 50 Over 50 Global List, and the EdelGive Hurun India Philanthropy rankings place her among the country’s most significant women philanthropists.
Building the cancer care infrastructure India lacks
In India, an estimated 1.46 million people are diagnosed with cancer every year. In very few of these cases is the patient actually sent to a specialist, and in even fewer can they afford the treatments that, in the higher-income world, have revolutionised survival. The Mazumdar-Shaw Cancer Centre at Narayana Health in Bangalore is providing affordable treatment to those referred from across Karnataka and surrounding states. The model allows them to treat those from lower socio-economic groups in a high-volume, low-unit-cost model, similar to how the same logic of scale used by Biocon applies to price points that, without a subsidy, keep costs contained.
What a Succession Plan Says About Legacy
The succession plan announced in 2026 by Mazumdar-Shaw named her niece, Claire Mazumdar, who runs Bicara Therapeutics in the US, as the person she sees leading Biocon into its new, technology-led biotech future, fueled by AI. It is important not just from a corporate governance perspective, but also as a declaration of her vision for Biocon’s future – as a biotechnology company, still rooted in the founder’s mission to make medicines affordable, yet pushing towards greater complexity and innovation. It is a more consciously planned statement about an enduring legacy than Indian philanthropy (and social business enterprise in India generally) too rarely makes.
Clear Cut CSR Desk
New Delhi, UPDATED: September 10, 2026 11:50 IST
Written By: Tanmay J. Urs
